Globenewswire·2025-09-23 05:00Core Insights - The FDA has granted fast track designation to Sanofi's SAR446268, a one-time AAV gene therapy for treating non-congenital myotonic dystrophy type 1 (DM1), aimed at expediting its development and review process [1][7] Group 1: Product Development - SAR446268 utilizes a vectorized RNA interference (RNAi) approach to silence DMPK expression, potentially addressing key symptoms of DM1 such as muscle weakness and myotonia [2][3] - The therapy is currently undergoing a first-in-human, phase 1-2 study to assess its safety, tolerability, and efficacy, with the first patient expected to be enrolled in late 2025 [3] Group 2: Disease Overview - Myotonic dystrophy type 1 is a rare genetic disorder affecting approximately 1 in 2,300 people globally, characterized by progressive muscle weakness and various systemic effects [4] - There are currently no approved treatments for DM1, highlighting the unmet medical need that SAR446268 aims to address [4][7] Group 3: Company Profile - Sanofi is an R&D driven biopharma company focused on improving lives through innovative medicines and vaccines, with a commitment to addressing urgent healthcare challenges [5]